JPH0217525B2 - - Google Patents
Info
- Publication number
- JPH0217525B2 JPH0217525B2 JP57001515A JP151582A JPH0217525B2 JP H0217525 B2 JPH0217525 B2 JP H0217525B2 JP 57001515 A JP57001515 A JP 57001515A JP 151582 A JP151582 A JP 151582A JP H0217525 B2 JPH0217525 B2 JP H0217525B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- water
- caries
- crude drug
- petroleum ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 claims description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 208000002925 dental caries Diseases 0.000 claims description 15
- 241000411851 herbal medicine Species 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000003208 petroleum Substances 0.000 claims description 7
- 241001071795 Gentiana Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 108010055629 Glucosyltransferases Proteins 0.000 claims description 3
- 102000000340 Glucosyltransferases Human genes 0.000 claims description 3
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 2
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 2
- 239000004075 cariostatic agent Substances 0.000 claims description 2
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 2
- 239000012259 ether extract Substances 0.000 claims 3
- 239000000401 methanolic extract Substances 0.000 claims 3
- 240000008866 Ziziphus nummularia Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 description 14
- 102100039604 mRNA guanylyltransferase Human genes 0.000 description 14
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 241001247821 Ziziphus Species 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000606 toothpaste Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 208000002064 Dental Plaque Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000736199 Paeonia Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 229940034610 toothpaste Drugs 0.000 description 5
- 244000215068 Acacia senegal Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920001503 Glucan Polymers 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000194019 Streptococcus mutans Species 0.000 description 4
- 239000000205 acacia gum Substances 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- -1 gargles Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- 239000000551 dentifrice Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000010015 huanglian Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940104261 taurate Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 241000124501 Paeonia obovata var. japonica Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 208000004042 dental fluorosis Diseases 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明はう蝕予防剤に関し、更に詳しくはグル
コシルトランスフエラーゼ阻害作用を有する生薬
抽出エキスを必須成分とするう蝕予防剤に関す
る。
う蝕の原因については、過去多数の研究者によ
つて多くの説が唱えられて来たが、今日では、ミ
ラー(Miller)らの化学細菌説から発展した細菌
感染疾患説が有力である。この説によれば、う蝕
は以下に述ぺる機構によつて発生する。即ち、口
腔内の微生物、特にストレプトコツカス・ミユー
タンス(Streptococcus mutans、以下S.mutans
という)の菌体外酵素であるグルコシルトランス
フエラーゼ(以下GTaseという)によつて食物
中の蔗糖が粘着性を有する多糖類(グルカン)に
変換され、このグルカンが歯面に付着して菌体の
凝集塊、即ち歯垢を形成する。この歯垢中で微生
物が増殖し、解糖系により乳酸などの有機酸が産
生する。この有機酸により歯面のPHが5.4以下に
なるとエテメル質に脱灰がおこり、う蝕が発生、
進行する。
以上のう蝕発生機構から明らかな様に、う蝕の
発生には1)食物成分、特に蔗糖、2)有機酸に
侵されやすい歯質、および3)口腔内微生物の三
大要因が必要である。従つて、う蝕を予防するに
は蔗糖を摂取しないか、歯質を強化するか、口腔
内微生物を死滅させればよい。この様な目的で、
従来から種々のう蝕予防処置がとられて来たが、
いづれも顕著な効果をあげるまでには至つていな
い。即ち、食物から蔗糖を完全に除去することは
現実的には不可能であり、またフツ素入り歯みが
きを使用したり水道水にフツ素を混入したりして
歯質を強化する方法も、その効果がそれほど大き
くない上に斑状歯になりやすいという副作用を伴
い、決して満足し得るものではない。一方、生成
した歯垢を分解する酵素入り歯みがきや口腔用殺
菌剤も市販されているが、その効果は期待された
ものとは、ほど遠いのが現状である。
本発明者らは、GTaseの不溶性のグルカン生
合成作用を阻害することによつて菌体の歯面への
付着を阻止し、歯垢の生成自体を防止し、もつて
う蝕の発生を防止するのが最も有効な方法の1つ
であることに着目し、この様な阻害物質を求めて
研究を重ねた結果、意外にも現在他の用途に使用
されている数多くの生薬抽出エキスにGTase阻
害作用があることを見い出し、本発明を完成する
に至つた。
即ち、本発明の目的は、S.Mutansの菌体外酵
素であるGTaseを阻害する生薬抽出エキスを必
須成分とするう蝕予防剤を提供することにある。
尚、本明細書に於て生薬抽出エキスとは、特に
明記しない限り、後述の方法によつて得られる生
薬抽出液、その希釈液、その濃縮エキスあるいは
その乾燥粉末を意味するものとする。
上記の目的に使用し得る代表的な生薬は、大棗
ウイキヨウ、芍薬、ゲンチアナ、センソ、白ホ、
龍胆、黄連、センブリおよび黄苓などである。こ
れらの生薬を、常法により適当な抽出溶媒で抽出
すれば、GTase阻害作用を有する生薬抽出エキ
スが得られる。
抽出溶媒としては、水、メタノール、エタノー
ルまたはアセトンの如き水混和性有機溶媒、ある
いは水とこれらの有機溶媒との混合物などを使用
することができ、さらに、エーテル、ヘキサンな
どの炭化水素系有機溶媒も使用することができ
る。
この様にして得られる生薬抽出エキスを単独
で、あるいは2種またはそれ以上を混合してその
まま使用するか、あるいは後述する様に、適当な
製剤化した後口腔内に適用すれば、S.Mutansの
菌体外酵素であるGTaseが不活性化され、歯垢
の生成が防止される。
本発明に係る1種またはその以上の生薬から得
られる生薬抽出エキスは、それが水抽出エキスの
場合、そのままあるいは適当に希釈して使用する
こともできるが、要すれば濃縮あるいは凍結乾燥
して粉末あるいはペースト状とした後、適当な口
腔用組成物の形に製剤化して使用するのが好まし
い。この様な口腔用組成物は液剤、固形剤、半固
形剤のいづれであつてもよく、好ましい組成物と
しては歯まがき剤、含嗽剤、トローチ剤、うがい
薬、塗布液剤、チユーインガムなどが挙げられ
る。
これらの口腔用組成物を製造するのに使用され
る賦形剤または補助剤は、通常この種の目的に使
用されるものから剤型に応じて適宜選択すればよ
く、特に制限されるものではないが、例えば乳
糖、デンプン、コーンスターチ、ステアリン酸マ
グネシウム、第2燐酸カルシウム・2水和物、ソ
ルビツト、カルボキシメチルセルロース、サツカ
リン、ラウリル硫酸ナトリウム、グリセリン、ソ
ジウムカルボキシメチルセルロース、無水ケイ
酸、ゼラチン、二酸化チタン、メントール、脂肪
酸、クエン酸、ポリエチレングリコール、ソジウ
ムラウロイルサルコシネート、炭酸カルシウム、
アルコール、カラゲナン、ソジウムアシルタウレ
ート、ペプトン、アラビアゴム、ラウリルジエタ
ノールアミドなどが好適に使用される。
上記の組成物に、クロルヘキシジンおよび塩化
ベンザルコニウムなどの殺菌剤を配合し、そのう
蝕予防効果を一層高めることもできるし、さらに
保存剤、香料および着色剤などを適宜添加するこ
ともできる。
この様にして製造されるう蝕予防用口腔組成物
中に占める生薬抽出エキスの量は剤型によつて異
なるが、通常濃縮エキス重量で約0.001%(重
量/重量)以上であることが望ましい。
各種生薬エキスのGTase阻害作用の測定
1 GTase酵素の調製
う蝕原性連鎖球菌ストレプトコツカス・ミユー
タンスOMZ176(血清型、d型)を斜面培地で2
回前培養した後ブレインハートインヒユージヨン
ブロスで24時間、37℃で培養し、5000rpmで10分
間遠心分離して培養上清を得た。氷冷下、この上
清に(NH4)2SO4を50%飽和となるまで添加して
塩析し、5000rpmで10分間遠心分離して沈澱物を
集めた。この沈澱物を1/1000M酢酸緩衝液に溶
解し、同一の緩衝液に対して4℃で18時間透析
し、GTase酵素標品液を得た。
2 生薬エキスの調製
生薬約1g〜10gに、その約10倍量の水、メタ
ノール、石油エーテルまたは水−メタノール混液
などの抽出液を加えて1時間振盪抽出するか、あ
るいは1時間マントルヒーター中で加熱還流下に
抽出した後、2500rpmで15分間遠心分離し、上澄
液を紙を用いて過し、減圧下に濃縮乾固す
る。得られるエキスの収率は、生薬の種類や抽出
溶媒によつて異なるが、1例を挙げれば表1の通
りである。
The present invention relates to a caries preventive agent, and more particularly to a caries preventive agent containing a herbal medicine extract having a glucosyltransferase inhibitory effect as an essential ingredient. Many researchers have proposed many theories regarding the cause of dental caries in the past, but today, the bacterial infection theory, developed from the chemical-bacteria theory of Miller et al., is the prevailing theory. According to this theory, caries occurs by the mechanism described below. That is, microorganisms in the oral cavity, especially Streptococcus mutans (hereinafter referred to as S.mutans),
Sucrose in food is converted into sticky polysaccharide (glucan) by glucosyltransferase (hereinafter referred to as GTase), which is an extracellular enzyme of bacterial cells. form agglomerates, that is, dental plaque. Microorganisms proliferate in this dental plaque, and organic acids such as lactic acid are produced through glycolysis. When the pH of the tooth surface drops below 5.4 due to this organic acid, demineralization occurs in the etemel, causing caries.
proceed. As is clear from the above caries development mechanism, three major factors are necessary for the development of caries: 1) food components, especially sucrose, 2) tooth structure that is easily attacked by organic acids, and 3) oral microorganisms. be. Therefore, to prevent dental caries, it is best to avoid sucrose intake, strengthen tooth structure, or kill oral microorganisms. For this purpose,
Various caries prevention measures have been taken in the past, but
None of them have reached the point where they have achieved any noticeable effects. In other words, it is practically impossible to completely remove sucrose from food, and there are also methods to strengthen tooth structure by using fluoride-containing toothpaste or adding fluoride to tap water. It is not very effective and has the side effect of causing mottled teeth, so it is by no means satisfactory. On the other hand, enzyme-containing toothpastes and oral disinfectants that decompose formed dental plaque are also commercially available, but their effectiveness is currently far from what was expected. The present inventors inhibited the insoluble glucan biosynthesis action of GTase, thereby preventing bacterial cells from adhering to the tooth surface, preventing the formation of dental plaque itself, and thereby preventing the development of dental caries. Focusing on the fact that this is one of the most effective methods, and as a result of repeated research in search of such inhibitors, we surprisingly found that GTase is present in many crude drug extracts currently used for other purposes. They discovered that it has an inhibitory effect and completed the present invention. That is, an object of the present invention is to provide an anti-caries agent containing as an essential ingredient a crude drug extract that inhibits GTase, which is an extracellular enzyme of S. Mutans. In this specification, unless otherwise specified, the crude drug extract means a crude drug extract obtained by the method described below, a diluted solution thereof, a concentrated extract thereof, or a dried powder thereof. Typical herbal medicines that can be used for the above purposes include daisy, peonies, gentian, senso, white ho,
These include Longtan, Huanglian, Oriental chinensis, and Huangli. If these crude drugs are extracted using a suitable extraction solvent using a conventional method, crude drug extracts having GTase inhibitory activity can be obtained. As the extraction solvent, water, water-miscible organic solvents such as methanol, ethanol, or acetone, or mixtures of water and these organic solvents can be used, and hydrocarbon-based organic solvents such as ether and hexane can be used. can also be used. If the crude drug extracts obtained in this way are used alone or in a mixture of two or more, or if applied to the oral cavity after forming into an appropriate formulation as described below, S. Mutans GTase, an extracellular enzyme of bacteria, is inactivated and the formation of dental plaque is prevented. If the herbal medicine extract obtained from one or more herbal medicines according to the present invention is an aqueous extract, it can be used as it is or diluted appropriately, but if necessary, it can be concentrated or lyophilized. It is preferable to formulate it into a powder or paste form and then formulate it into a suitable oral composition before use. Such oral compositions may be in the form of liquids, solids, or semi-solids, and preferred compositions include toothpastes, gargles, lozenges, gargles, liniments, and chewing gums. It will be done. The excipients or auxiliary agents used to produce these oral compositions may be appropriately selected from those normally used for this type of purpose depending on the dosage form, and are not particularly limited. However, for example, lactose, starch, corn starch, magnesium stearate, dicalcium phosphate dihydrate, sorbitol, carboxymethylcellulose, saccharin, sodium lauryl sulfate, glycerin, sodium carboxymethylcellulose, silicic anhydride, gelatin, titanium dioxide , menthol, fatty acids, citric acid, polyethylene glycol, sodium lauroyl sarcosinate, calcium carbonate,
Alcohol, carrageenan, sodium acyl taurate, peptone, gum arabic, lauryl diethanolamide and the like are preferably used. A bactericidal agent such as chlorhexidine and benzalkonium chloride can be added to the above composition to further enhance its caries prevention effect, and a preservative, fragrance, coloring agent, etc. can also be added as appropriate. The amount of the herbal medicine extract in the oral composition for caries prevention produced in this way varies depending on the dosage form, but it is usually desirable that it be approximately 0.001% (weight/weight) or more by weight of the concentrated extract. . Measurement of GTase inhibitory effect of various crude drug extracts 1 Preparation of GTase enzyme Cariogenic streptococcus Streptococcus miutans OMZ176 (serotype, type d) was grown in slant culture medium.
After pre-culture, the cells were cultured in brain heart infusion broth for 24 hours at 37°C and centrifuged at 5000 rpm for 10 minutes to obtain a culture supernatant. Under ice-cooling, (NH 4 ) 2 SO 4 was added to the supernatant until it reached 50% saturation for salting out, and the precipitate was collected by centrifugation at 5000 rpm for 10 minutes. This precipitate was dissolved in 1/1000M acetate buffer and dialyzed against the same buffer at 4°C for 18 hours to obtain a GTase enzyme preparation solution. 2. Preparation of crude drug extract Add about 10 times the amount of extract liquid such as water, methanol, petroleum ether or water-methanol mixture to about 1 g to 10 g of crude drug and extract by shaking for 1 hour or in a mantle heater for 1 hour. After extraction under heating and reflux, centrifugation is performed at 2500 rpm for 15 minutes, the supernatant liquid is filtered through paper, and concentrated to dryness under reduced pressure. The yield of the obtained extract varies depending on the type of crude drug and extraction solvent, but an example is shown in Table 1.
【表】
3 GTase阻害活性の測定
0.04%NaN2水溶液中の20%蔗糖溶液500μl、
200mM酢酸緩衝液(PH7.5)200μl、生薬抽出エ
キス(原液、×10、×100、または×1000倍液)
200μlおよびGTase酵素標品液100μlを混合し、37
℃で18時間培養する。10%トリクロル酢酸100μl
を加えて反応を終了させ、13000rpmで5分間遠
心分離する。上清をデカントして捨て、沈渣を水
1mlで3回、次いでアセトン1mlで3回洗浄した
後乾燥し、1M−NaOH1mlを加えて一夜放置し、
完全に溶解させる。この溶液100μlを1MNaOHで
20〜30倍に希釈し、GTaseの作用で生成した不
溶性グルカンをフエノール硫酸法※
により定量す
る。生薬エキスの代りに蒸留水を用いて同様の操
作を行なつてコントロールとし、以下の式から
GTase阻害率を計算する。
GTase阻害率(%)
=(1−サンプルのOD490nm/コントールのOD490nm
)×100
フエノール硫酸法:グルカン含有NaOH溶液
200μl、5%フエノール水溶液200μlおよび濃硫酸
1mlの混合物をよく撹拌し、490nmにおける吸光
度(OD490nm)を測定する。
各種の生薬抽出エキスを用いて行なつた実験の
結果を以下の表2に示す。[Table] 3 Measurement of GTase inhibitory activity 500 μl of 20% sucrose solution in 0.04% NaN 2 aqueous solution,
200 μl of 200 mM acetate buffer (PH7.5), crude drug extract (undiluted solution, ×10, ×100, or ×1000 solution)
Mix 200 μl and 100 μl of GTase enzyme standard solution,
Incubate for 18 hours at °C. 100 μl of 10% trichloroacetic acid
to terminate the reaction, and centrifuged at 13,000 rpm for 5 minutes. The supernatant was decanted and discarded, and the precipitate was washed three times with 1 ml of water and then three times with 1 ml of acetone, dried, added with 1 ml of 1M NaOH, and left overnight.
Dissolve completely. Add 100μl of this solution to 1M NaOH.
Dilute 20-30 times and quantify insoluble glucan produced by the action of GTase using the phenol-sulfuric acid method*. A similar operation was performed using distilled water instead of the herbal medicine extract as a control, and from the following formula:
Calculate the GTase inhibition rate. GTase inhibition rate (%) = (1-Sample OD490nm/Control OD490nm
)×100 Phenol sulfuric acid method: Glucan-containing NaOH solution
A mixture of 200 μl, 200 μl of 5% aqueous phenol solution, and 1 ml of concentrated sulfuric acid is stirred well, and the absorbance at 490 nm (OD490 nm) is measured. The results of experiments conducted using various crude drug extracts are shown in Table 2 below.
【表】【table】
【表】
* 酵素反応液中での濃縮エキスの濃度
表2から大棗、ウイキヨウ、芍薬およびゲンチ
アナは強い阻害活性を有することがわかる。これ
らは0.0001%〜0.001%の低濃度でも有意な活性
を保持していることがわかつた。この様に、広い
濃度範囲において活性を示す生薬抽出エキスは、
う蝕防止用口腔組成物を製造するのに特に有用で
ある。
以下に生薬エキスの抽出法および該エキスを必
須成分とするう蝕予防剤の製造法についての実施
例を挙げる。
実施例 1
大棗を細かく破砕し、この10gを200mlのテス
型フラスコに入れ、水100mlを加え、還流冷却器
を付して直火で1時間還流した後、減圧下で濃縮
して大棗水抽出濃縮エキス3.4gを得た。冷水で
振盪抽出した場合もほぼ同量の濃縮エキスが得ら
れた。
センソは粉砕した後、芍薬、ウイキヨウ、ゲン
チアナ、白ボ、龍胆、黄連、センブリおよび黄苓
は、生薬粉末をそのまま使用し、上記と同様にし
て生薬水抽出エキスを得た。
実施例 2
水の代りにメタノール、水とエタノールの混合
溶媒および石油エーテルを用いるほかは実施例1
と同様の操作を行なつた。得られた濃縮エキスの
量はメタノールの場合2.8g、水/エタノールの
場合3.0g、石油エーテルの場合0.4gであつた。
実施例3 歯磨剤
第2リン酸カルシウム 42
グリセリン 18
カラギーナン 0.9
ラウリル硫酸ナトリウム 1.2
サツカリン 1.0
珍大棗エキス※ 0.005
パラオキシ安息香酸ブチル 0.005
香料 1.1
水 残量
全量 100(重量%)
生薬エキスは水又はMeOH又は石油エーテル
抽出濃縮エキス。以下の実施例に於ても同じ。
練り歯磨剤の製造の常法に従つて製造する。即
ち、水、グリセリン、カラギーナン、サツカリ
ン、大棗エキス、パラオキシ安息香酸ブチル、香
料の処方量を計量し、混合して粘結剤を膨潤させ
たのち、第2リン酸カルシウム、ラウリル硫酸ナ
トリウルを加え更に混合する。よく脱泡混合した
のちチユーブ充填する。
実施例4 含嗽剤
常法に従つて、下記処方の含嗽剤を製造する。
エタノール(90%) 20
サツカリン 0.3
ソジウムアシルタウレート 0.5
ゼラチン 0.5
ウイキヨウエキス 0.005
香料 1.0
クロルヘキシジン 0.005
水 残量
全量 100(重量%)
実施例5 トローチ剤
アラビアゴム 8
白糖 70
芍薬エキス 0.005
大棗エキス 0.005
香料 1.0
乳糖 17.0
ステアリン酸マグネシウム 適量
全量 100(重量%)
アラビアゴム、白糖、乳糖、芍薬エキス、大棗
エキス、香料に水を加え、練合後、適当な造粒機
で造粒後、乾燥する。12メツシユフルイを通して
粒を整えたのち、ステアリン酸マグネシウムを加
えて、適当な形状に打錠する。
実施例6 チユーインガム
常法に従つて下記処方のチユーインガムを製造
する。
ガムベース 20
炭酸カルシウム 2
サツカリン 0.1
大棗エキス 0.005
乳糖 74.9
香料 1
全量 100(重量%)
実施例7 歯磨粉
常法に従い下記処方の歯磨粉を製造する。
第2リン酸カルシウム・2水和物 50
炭酸カルシウム 25
グリセリン 10
ラウリル硫酸ナトリウム 1.3
クロルヘキシジンジグルコネート 0.5
ゲンチアナエキス 0.01
サツカリン 0.1
香料 1
水 残量
全量 100(重量%)
実施例8 トローチ剤
常法に従い、下記処方のトローチ剤を製造す
る。
アラビアゴム 6
ブドウ糖 72
ウイキヨウエキス 0.05
大棗エキス 0.005
リン酸二カリウム 0.2
リン酸一カリウム 0.1
香料 1.0
乳糖 17.0
ステアリン酸マグネシウム 適量
全量 100(重量%)
実施例9 2種の生薬エキスを配合した歯磨剤常
法に従い、下記処方の練り歯磨剤を製造する。
ピロリン酸カルシウム 42
ラウリル硫酸ナトリウム 1.2
ソジウムラウロイルザルコシネート 0.2
グリセリン 20
カラギーナン 1.1
シヨ糖脂肪酸エステル 2.0
芍薬エキス 0.06
大棗エキス 0.06
クロルヘキシジンジグルコネート 0.5
サツカリン 0.1
香料 1.2
水 残量
全量 100(重量%)[Table] *Concentration of concentrated extract in enzyme reaction solution From Table 2, it can be seen that Japanese jujube, fenugreek, peony, and gentian have strong inhibitory activity. These were found to retain significant activity even at low concentrations of 0.0001% to 0.001%. In this way, crude drug extracts that exhibit activity over a wide concentration range are
It is particularly useful for producing anti-caries oral compositions. Examples of methods for extracting crude drug extracts and methods for producing caries preventive agents containing the extracts as an essential ingredient are listed below. Example 1 Finely crush a large jujube, put 10 g of this into a 200 ml Tess-type flask, add 100 ml of water, attach a reflux condenser and reflux for 1 hour over an open flame, and then concentrate under reduced pressure to form a large jujube. 3.4 g of water-extracted concentrated extract was obtained. Almost the same amount of concentrated extract was obtained when shaking and extracting with cold water. After pulverizing Senso, herbal medicine powders were used as they were for Paeonia japonica, Urticaria, gentian, Baibo, Longtan, Huanglian, Oriental japonica, and Huanglin, and the water extracts of herbal medicines were obtained in the same manner as above. Example 2 Example 1 except that methanol, a mixed solvent of water and ethanol, and petroleum ether are used instead of water.
The same operation was performed. The amount of concentrated extract obtained was 2.8 g for methanol, 3.0 g for water/ethanol, and 0.4 g for petroleum ether. Example 3 Dentifrice Dibasic calcium phosphate 42 Glycerin 18 Carrageenan 0.9 Sodium lauryl sulfate 1.2 Saccharin 1.0 Jujube extract* 0.005 Butyl paraoxybenzoate 0.005 Fragrance 1.1 Water Total remaining amount 100 (wt%) Herbal extract is water, MeOH or petroleum ether Concentrated extract. The same applies to the following examples. Manufactured according to conventional methods for manufacturing toothpaste. That is, the prescribed amounts of water, glycerin, carrageenan, saccharin, jujube extract, butyl paraoxybenzoate, and fragrance are measured and mixed to swell the binder, and then dibasic calcium phosphate and sodium lauryl sulfate are added and further mixed. do. After thoroughly defoaming and mixing, fill the tube. Example 4 Mouthwash A mouthwash having the following formulation is manufactured according to a conventional method. Ethanol (90%) 20 Satucalin 0.3 Sodium acyl taurate 0.5 Gelatin 0.5 Wickerberry extract 0.005 Flavor 1.0 Chlorhexidine 0.005 Water Total remaining amount 100 (wt%) Example 5 Lozenge Gum Arabic 8 White sugar 70 Paeonia extract 0.005 Jujube extract 0.00 5 Flavoring 1.0 Lactose 17.0 Magnesium stearate Appropriate amount Total amount 100 (wt%) Add water to gum arabic, white sugar, lactose, peonies extract, jujube extract, fragrance, mix, then granulate with a suitable granulator and dry. . 12 After adjusting the grains through a mesh filter, add magnesium stearate and tablet into an appropriate shape. Example 6 Chewing Gum Chewing gum having the following formulation is manufactured according to a conventional method. Gum base 20 Calcium carbonate 2 Saccharin 0.1 Jujube extract 0.005 Lactose 74.9 Flavor 1 Total amount 100 (wt%) Example 7 Toothpaste A toothpaste with the following formulation is manufactured according to a conventional method. Dicalcium phosphate dihydrate 50 Calcium carbonate 25 Glycerin 10 Sodium lauryl sulfate 1.3 Chlorhexidine digluconate 0.5 Gentiana extract 0.01 Satucharin 0.1 Flavoring 1 Water Total amount remaining 100 (wt%) Example 8 Lozenge The following formulation according to the conventional method Manufacture lozenges. Gum arabic 6 Glucose 72 Wickerberry extract 0.05 Jujube extract 0.005 Dipotassium phosphate 0.2 Monopotassium phosphate 0.1 Flavoring 1.0 Lactose 17.0 Magnesium stearate Appropriate total amount 100 (% by weight) Example 9 Dentifrice containing two types of crude drug extracts A toothpaste with the following formulation is manufactured according to a conventional method. Calcium pyrophosphate 42 Sodium lauryl sulfate 1.2 Sodium lauroyl sarcosinate 0.2 Glycerin 20 Carrageenan 1.1 Sucrose fatty acid ester 2.0 Paeonia extract 0.06 Jujube extract 0.06 Chlorhexidine digluconate 0.5 Satucalin 0.1 Flavor 1.2 Water Total remaining amount 100 (wt%)
Claims (1)
する生薬抽出エキスを必須成分とするう蝕予防剤
であつて、該生薬抽出エキスが大棗の水エキス、
メタノールエキス、石油エーテルエキス、ウイキ
ヨウの水エキス、メタノールエキス、石油エーテ
ルエキス、ゲンチアナのメタノールエキス、石油
エーテルエキス、およびセンソ、龍胆、当薬の
各々水エキスからなる群から選ばれる1種または
それ以上の生薬抽出エキスであることを特徴とす
るう蝕予防剤。 2 生薬抽出エキスの含量が濃縮エキスで0.001
重量%以上である特許請求の範囲第1項に記載の
う蝕予防剤。[Scope of Claims] 1. An anti-caries agent containing a crude drug extract having a glucosyltransferase inhibitory effect as an essential ingredient, wherein the crude drug extract is a water extract of large jujube,
One or more selected from the group consisting of methanol extract, petroleum ether extract, fenugreek water extract, methanol extract, petroleum ether extract, gentian methanol extract, petroleum ether extract, and water extracts of each of Senso, Longtan, and this drug. A caries prevention agent characterized by being an extract of the above herbal medicine. 2 The content of herbal medicine extract is 0.001 as a concentrated extract.
The caries preventive agent according to claim 1, which is at least % by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57001515A JPS58121218A (en) | 1982-01-07 | 1982-01-07 | Tooth decay preventive |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57001515A JPS58121218A (en) | 1982-01-07 | 1982-01-07 | Tooth decay preventive |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58121218A JPS58121218A (en) | 1983-07-19 |
JPH0217525B2 true JPH0217525B2 (en) | 1990-04-20 |
Family
ID=11503616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57001515A Granted JPS58121218A (en) | 1982-01-07 | 1982-01-07 | Tooth decay preventive |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58121218A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0566021U (en) * | 1992-02-18 | 1993-08-31 | 日本ソリッド株式会社 | Cylindrical head protector |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60228419A (en) * | 1984-04-27 | 1985-11-13 | Kao Corp | Preventive for gingivitis |
JPH0635377B2 (en) * | 1984-07-30 | 1994-05-11 | ライオン株式会社 | Oral composition |
JPS62155210A (en) * | 1985-12-27 | 1987-07-10 | Lion Corp | Composition for oral cavity |
JPH0791178B2 (en) * | 1986-09-03 | 1995-10-04 | ライオン株式会社 | Oral composition |
US5009886A (en) * | 1989-10-02 | 1991-04-23 | Floss Products Corporation | Dentifrice |
JPH05255098A (en) * | 1992-03-09 | 1993-10-05 | Kanebo Ltd | Dental caries preventive |
JP2005008539A (en) * | 2003-06-17 | 2005-01-13 | Fancl Corp | Matrix metalloproteinase inhibitor |
JP4606715B2 (en) * | 2003-09-05 | 2011-01-05 | 救心製薬株式会社 | Immune activity enhancer, and food and quasi drug containing the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5756415A (en) * | 1980-09-20 | 1982-04-05 | Lion Corp | Composition for oral cavity |
JPS5758611A (en) * | 1980-09-26 | 1982-04-08 | Lion Corp | Composition for oral cavity application |
JPS5785610A (en) * | 1980-11-14 | 1982-05-28 | Hitachi Ltd | Guide device for rolling mill |
JPS5785319A (en) * | 1980-11-16 | 1982-05-28 | Tsurui Yakuhin Kogyo Kk | Agent for dental caries |
JPS5839615A (en) * | 1981-09-03 | 1983-03-08 | Lion Corp | Dentrifrice composition |
JPS5857320A (en) * | 1981-10-01 | 1983-04-05 | Tsurui Yakuhin Kogyo Kk | Plaque formation inhibitor |
-
1982
- 1982-01-07 JP JP57001515A patent/JPS58121218A/en active Granted
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5756415A (en) * | 1980-09-20 | 1982-04-05 | Lion Corp | Composition for oral cavity |
JPS5758611A (en) * | 1980-09-26 | 1982-04-08 | Lion Corp | Composition for oral cavity application |
JPS5785610A (en) * | 1980-11-14 | 1982-05-28 | Hitachi Ltd | Guide device for rolling mill |
JPS5785319A (en) * | 1980-11-16 | 1982-05-28 | Tsurui Yakuhin Kogyo Kk | Agent for dental caries |
JPS5839615A (en) * | 1981-09-03 | 1983-03-08 | Lion Corp | Dentrifrice composition |
JPS5857320A (en) * | 1981-10-01 | 1983-04-05 | Tsurui Yakuhin Kogyo Kk | Plaque formation inhibitor |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0566021U (en) * | 1992-02-18 | 1993-08-31 | 日本ソリッド株式会社 | Cylindrical head protector |
Also Published As
Publication number | Publication date |
---|---|
JPS58121218A (en) | 1983-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS647964B2 (en) | ||
KR930000059B1 (en) | Dental composition | |
JPH0217525B2 (en) | ||
JPWO2004026273A1 (en) | Oral composition | |
KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
JPS6258328B2 (en) | ||
JP2001089385A (en) | Anti-dental caries agent | |
JPH0495020A (en) | Enzyme inhibitor | |
JP2005035907A (en) | Anti-periodontal disease medicine | |
JPS6258329B2 (en) | ||
JPH11343247A (en) | Glucosyltransferase inhibitor | |
JP3281716B2 (en) | Glucosyltransferase inhibitors, oral preparations and foods and drinks | |
JP3319748B2 (en) | Caries inhibitor | |
JP4633399B2 (en) | Glucosyltransferase inhibitor | |
JP3472172B2 (en) | Oral agent | |
JP2763824B2 (en) | Oral composition | |
JP2001097835A (en) | Dental caries inhibitor | |
JP4585066B2 (en) | Caries inhibitor, oral preparation and food and drink | |
KR100387091B1 (en) | Composition for enhancing oral hygiene containing extract of safflower seed | |
JP3281458B2 (en) | Glucosyltransferase inhibitors | |
JP2002187843A (en) | Glucosyltransferase inhibitor | |
JPS6258324B2 (en) | ||
JPH10139646A (en) | Glucosyltransferase inhibitor, oral cavity composition and food and beverage | |
KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
JP4672096B2 (en) | Anti-caries agent and oral composition containing the same |